Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA

Model scores of the 29,894 trials active now.

Model score 29% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patients mustcombinationtherapychemotherapyct
  Phrases that lowered it: diseasesgastrointestinalpatients whomedicineintestinal
• Sponsor's past termination rate: 20% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Keywords listed: 31 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 10.1% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 70.2% (lowers risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 12756 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 17 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Sponsor's past trials: 30 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer NCT02969681 · started 2017 · scored riskier than 18% of active trials completed
• Evaluation of Intravenous Ascorbic Acid NCT01833351 · started 2011 · scored riskier than 24% of active trials completed
• AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer NCT00535353 · started 2008 · scored riskier than 49% of active trials completed
• A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective NCT01754987 · started 2012 · scored riskier than 98% of active trials completed
• A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer NCT01729923 · started 2013 · scored riskier than 73% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.